Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Evaluation of the methods to identify patients who may benefit from PARP inhibitor use.

Endocrine-related cancer - 1 Jun 2016

Lim Diana, Ngeow Joanne

Abstract excerpt

The effectiveness of poly (ADP-ribose) polymerase inhibitors (PARPi) in treating cancers associated with BRCA1/2 mutations hinges upon the concept of synthetic lethality and exemplifies the principles of precision medicine. Currently, most clinical trials are recruiting patients based on pathological subtypes or have included BRCA mutation analysis (germ line and/or somatic) as part of the selection criteria....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Biomarkers
Share to BRCA1 Protein

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to BRCA2 Protein

Share to DNA Damage

Share to DNA Repair

Share to Poly(ADP-ribose) Polymerase Inhibitors

Share to Poly(ADP-ribose) Polymerases

Source

Identifiers

PMID: 27226207
DOI: 10.1530/ERC-16-0116

Genes

BRCA1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Evaluation of the methods to identify patients who may benefit from PARP inhibitor use.PMID 27226207Read ↗

Predictors and Modulators of Synthetic Lethality: An Update on PARP Inhibitors and Personalized MedicineSemantic proximity Read ↗

Biomarkers beyond BRCA: promising combinatorial treatment strategies in overcoming resistance to PARP inhibitorsSemantic proximity Read ↗

Predictive biomarkers for cancer therapy with PARP inhibitors.Semantic proximity Read ↗

Integrated, Integral, and Exploratory Biomarkers in the Development of Poly(ADP-Ribose) Polymerase Inhibitors.Semantic proximity Read ↗

Cancer treatment according to BRCA1 and BRCA2 mutations.Semantic proximity Read ↗

Testing for homologous recombination repair or homologous recombination deficiency for poly (ADP-ribose) polymerase inhibitors: A current perspectiveSemantic proximity Read ↗

Potential agnostic role of BRCA alterations in patients with several solid tumors: One for all, all for one?Semantic proximity Read ↗

Role of Biomarkers in the Development of PARP InhibitorsSemantic proximity Read ↗

Development of PARP inhibitors in oncologySemantic proximity Read ↗

Targeting PARP1: A Promising Approach for Next-Generation Poly (ADP-ribose) Polymerase InhibitorsSemantic proximity Read ↗

Theranostic biomarkers and PARP-inhibitors effectiveness in patients with non-BRCA associated homologous recombination deficient tumors: Still looking through a dirty glass window?Semantic proximity Read ↗

BRCA in breast cancer: from risk assessment to therapeutic prediction.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.